CONTEXT: Insulin-requiring diabetes affects 7-15% of teens and young adults, and more than 25% of older adults with cystic fibrosis (CF). Pancreatic exocrine disease caused by CF transmembrane conductance regulator (CFTR) dysfunction underlies the high rate of diabetes in CF patients; however, only a subset develops this complication, indicating that other factors are necessary. OBJECTIVE: Our objective was to estimate the relative contribution of genetic and nongenetic modifiers to the development of diabetes in CF. DESIGN/PATIENTS: This was a twin and sibling study involving 1366 individuals at 109 centers in the CF Twin and Sibling Study, from which were derived 68 monozygous twin pairs, 23 dizygous twin pairs, and 588 sibling pairs, all with CF. MAIN OUTCOME MEASURE: Chronic, insulin-requiring diabetes in the setting of CF, as established using longitudinal clinical and biochemical data, was studied. RESULTS: About 9% of this predominantly pediatric population (mean age = 15.8 yr) had diabetes. Key independent risk factors identified by regression modeling included having a twin or sibling with CF and diabetes, increasing age, pancreatic exocrine insufficiency or two mutations causing severe CFTR dysfunction, decreased lung function or decreased body mass index, and longer duration of glucocorticoid treatment. The concordance rate for diabetes was substantially higher in monozygous twins (0.73) than in dizygous twins and siblings with CF (0.18; P = 0.002). Heritability was estimated as near one (95% confidence interval 0.42-1.0). CONCLUSIONS: Diabetes is a frequent complication of CF that is associated with worse outcomes. Although a nongenetic factor (steroid treatment) contributes to risk, genetic modifiers (i.e. genes other than CFTR) are the primary cause of diabetes in CF.
CONTEXT: Insulin-requiring diabetes affects 7-15% of teens and young adults, and more than 25% of older adults with cystic fibrosis (CF). Pancreatic exocrine disease caused by CF transmembrane conductance regulator (CFTR) dysfunction underlies the high rate of diabetes in CF patients; however, only a subset develops this complication, indicating that other factors are necessary. OBJECTIVE: Our objective was to estimate the relative contribution of genetic and nongenetic modifiers to the development of diabetes in CF. DESIGN/PATIENTS: This was a twin and sibling study involving 1366 individuals at 109 centers in the CF Twin and Sibling Study, from which were derived 68 monozygous twin pairs, 23 dizygous twin pairs, and 588 sibling pairs, all with CF. MAIN OUTCOME MEASURE: Chronic, insulin-requiring diabetes in the setting of CF, as established using longitudinal clinical and biochemical data, was studied. RESULTS: About 9% of this predominantly pediatric population (mean age = 15.8 yr) had diabetes. Key independent risk factors identified by regression modeling included having a twin or sibling with CF and diabetes, increasing age, pancreatic exocrine insufficiency or two mutations causing severe CFTR dysfunction, decreased lung function or decreased body mass index, and longer duration of glucocorticoid treatment. The concordance rate for diabetes was substantially higher in monozygous twins (0.73) than in dizygous twins and siblings with CF (0.18; P = 0.002). Heritability was estimated as near one (95% confidence interval 0.42-1.0). CONCLUSIONS:Diabetes is a frequent complication of CF that is associated with worse outcomes. Although a nongenetic factor (steroid treatment) contributes to risk, genetic modifiers (i.e. genes other than CFTR) are the primary cause of diabetes in CF.
Authors: M Cotellessa; L Minicucci; M C Diana; F Prigione; L Di Febbraro; R Gagliardini; A Manca; F Battistini; G Taccetti; G Magazzù; R Padoan; G Pizzamiglio; V Raia; L Iapichino; F Cardella; G Grinzich; V Lucidi; G Tuccio; E Bignamini; D Salvatore; R Lorini Journal: J Pediatr Endocrinol Metab Date: 2000 Sep-Oct Impact factor: 1.634
Authors: Melis A Aksit; Rhonda G Pace; Briana Vecchio-Pagán; Hua Ling; Johanna M Rommens; Pierre-Yves Boelle; Loic Guillot; Karen S Raraigh; Elizabeth Pugh; Peng Zhang; Lisa J Strug; Mitch L Drumm; Michael R Knowles; Garry R Cutting; Harriet Corvol; Scott M Blackman Journal: J Clin Endocrinol Metab Date: 2020-05-01 Impact factor: 5.958
Authors: Aliye Uc; Dana K Andersen; Melena D Bellin; Jason I Bruce; Asbjørn M Drewes; John F Engelhardt; Christopher E Forsmark; Markus M Lerch; Mark E Lowe; Brent A Neuschwander-Tetri; Stephen J OʼKeefe; Tonya M Palermo; Pankaj Pasricha; Ashok K Saluja; Vikesh K Singh; Eva M Szigethy; David C Whitcomb; Dhiraj Yadav; Darwin L Conwell Journal: Pancreas Date: 2016-11 Impact factor: 3.327
Authors: Weili Li; David Soave; Melissa R Miller; Katherine Keenan; Fan Lin; Jiafen Gong; Theodore Chiang; Anne L Stephenson; Peter Durie; Johanna Rommens; Lei Sun; Lisa J Strug Journal: Hum Genet Date: 2013-09-22 Impact factor: 4.132
Authors: Deanna M Green; Kathryn E McDougal; Scott M Blackman; Patrick R Sosnay; Lindsay B Henderson; Kathleen M Naughton; J Michael Collaco; Garry R Cutting Journal: Respir Res Date: 2010-10-08
Authors: Antoinette Moran; Dorothy Becker; Samuel J Casella; Peter A Gottlieb; M Sue Kirkman; Bruce C Marshall; Bonnie Slovis Journal: Diabetes Care Date: 2010-12 Impact factor: 19.112